Human recombinant tissue-plasminogen activator (alteplase): why not use the ‘human' dose for stroke studies in rats?

Since a pioneer work that has shown in vitro that the rat's fibrinolytic system is 10-fold less sensitive to recombinant tissue-plasminogen activator (rtPA) than the human system, most preclinical studies are performed with 10 instead of 0.9 mg/kg rtPA (the clinical dose in stroke patients). In...

Full description

Saved in:
Bibliographic Details
Main Authors: Haelewyn, Benoît, Risso, Jean-Jacques, Abraini, Jacques H
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2010
Subjects:
Brief Communication
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2949192/
https://ncbi.nlm.nih.gov/pubmed/20216551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jcbfm.2010.33
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items